南京 肺癌内科精准治疗1.pptVIP

 * * * Median PFS 10.9 vs. 7.0 months (crizotinib vs. chemotherapy; HR, 0.45; P0.0001) Median duration of follow-up for OS: 17 months in both treatment arms With 68% of patients still in follow-up, median OS was not reached in either arm * TKI耐药策略 * * 维持治疗 维持组 让更多患者接受有效治疗 不维持 力比泰(n=359)：中位6.90个月 安慰剂 (n=180) : 中位5.59个月 未调整HR : 0.59 95%CI=0.47-0.74) p0.00001 时间 (月) 0 3 6 9 12 15 18 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 PFS 1.0 0.8 0.6 0.4 0.2 0.0 0 6 12 18 24 30 36 力比泰 (n=359)：中位16.9个月 安慰剂 (n-180)： 中位14.0个月 OS 时间 (月) HR=0.78 95%CI=0.64-0.96 P=0.0191 PFS Paz-Ares LG, et al. J Clin